All nine subjects of Phase 1 injected without any serious adverse events. Average improvement of 14.9 letters in visual acuity reported in the first six patients over a four-six month follow-up. Signs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback